Evaluation of the anti‐inflammatory effect of infliximab in a mouse model of acute asthma
- 10 April 2008
- journal article
- Published by Wiley in Respirology
- Vol. 13 (4), 488-497
- https://doi.org/10.1111/j.1440-1843.2008.01278.x
Abstract
Background and objective: To evaluate the potential role of anti‐tumour necrosis factor (TNF)‐α mAb (infliximab) on the inflammatory response in a mouse model of acute asthma.Methods: BALB/c mice received intraperitoneal (i.p.) ovalbumin (OVA) on days 0 and 14, 100 μg of OVA intranasally on day 14 and 50 μg of OVA intranasally on days 25, 26 and 27. The low‐dose (2.5 mg/kg) and high‐dose (6.25 mg/kg) infliximab groups received i.p. infliximab before each i.p. sensitization and on challenge days 1, 6, 13, 20 and 27. The control group received i.p. injections of normal saline with alum on days 0 and 14 and normal saline without alum on days 14, 25, 26 and 27.Results: There were statistically significant decreases in the numbers of BAL fluid (BALF) neutrophils, eosinophils, as well as lung eosinophils in both the low‐ and high‐dose infliximab groups when compared with the control OVA sensitized/challenged group. The lower dose of infliximab did not alter lung neutrophil counts, but a marked decrease was seen with the high dose of infliximab. After treatment with low and high doses of infliximab, BALF levels of regulated on activation normal T cell expressed and secreted (RANTES), granulocyte macrophage‐colony stimulating factor (GM‐CSF), TNF‐α, IL‐6, macrophage inflammatory protein (MIP)‐2, and levels of RANTES, IL‐4, GM‐CSF, TNF‐α, IL‐6 and MIP‐2 in lung tissue were significantly decreased when compared with the control OVA sensitized/challenged group. There was a significant decrease in BALF IL‐4 only in the high‐dose infliximab group.Conclusions: These results show that an anti‐TNF‐α mAb has a considerable anti‐inflammatory effect on allergen‐induced lung inflammation in an animal model of acute asthma.Keywords
This publication has 53 references indexed in Scilit:
- Infliximab for chronic obstructive pulmonary disease: towards a more specific inflammation targeting?Expert Opinion on Investigational Drugs, 2006
- Clinical Response of Rheumatoid Arthritis-Associated Pulmonary Fibrosis to Tumor Necrosis Factor-α InhibitionChest, 2002
- Tumour necrosis factor‐α: The role of this multifunctional cytokine in asthmaImmunology & Cell Biology, 2001
- Cytokines in asthmaThorax, 1999
- Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitisGastroenterology, 1999
- Expression of RANTES in human airway epithelial cells: effect of corticosteroids and interleukin‐4, ‐10 and ‐13Immunology, 1996
- Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor αArthritis & Rheumatism, 1993
- Construction and initial characterization of a mouse-human chimeric anti-TNF antibodyMolecular Immunology, 1993
- Proinflammatory cytokines in acute asthmaThe Lancet, 1991
- Neutrophil Chemotactic Activity in Antigen-Induced Late Asthmatic ReactionsNew England Journal of Medicine, 1982